ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera announced 20 abstracts featuring its technology at the 2026 ESMO Annual Congress, October 23-26 in Madrid, including 4 rapid oral presentations. The program features Signatera Genome with Phased and Structural Variants, which achieved an LOD95 below 1 part per million and detection significantly below 1 part per 10 million. Highlighted data include the ICONIC trial in gastroesophageal cancer showing a >7.3-month median lead time over imaging, and the phase III SAGITTARIUS trial in colon cancer where Signatera results changed pre-planned treatment for one in three patients, 87% of whom were de-escalated on MRD negativity.
Key figures
- Lod95
- below 1 part per million
- Abstracts
- 20
- Iconic median lead time
- >7.3 months over standard imaging
- Rapid oral presentations
- 4
- Sagittarius deescalation rate
- 87%
- Sagittarius treatment change rate
- one in three patients
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.